Age 9–45 males with FXS with a molecular genetic confirmation FMR1 >200 CGG repetitions needed for clinical trials of new drug zatolmilast.
Tetra Therapeutics is conducting two randomized, placebo-controlled studies of BPN14770 (zatolmilast) to learn about the experimental drug’s safety and efficacy. Both trials will be followed by an open label extension study. If results are positive, Tetra will be seeking approval of the drug with the FDA.
One trial is for adolescent males ages 9 to <18 years old and the other trial is for adult males 18-45 years.
About the Study
Who can participate?
Males ages 9–45 may be eligible to participate with a molecular genetic confirmation of FXS: FMR1 >200 CGG repetitions.
What will happen in the study?
If the individual qualifies and decides to be in this research study, they will conduct eight visits (at clinic and at home) over 13 weeks.
The following is a list of some of the study procedures that will happen during the study:
- Participant cognitive and behavior testing
- Blood draws
- Parent/caregiver questionnaires
For more information, visit Tetra’s website.
What are the good things that can happen from this research?
Potential benefits are improvement in cognitive (language and vocabulary) function and improvement in daily activities/behavior.
What are the bad things that can happen from this research?
Potential drug side effects include mild nausea and diarrhea.
There may be other risks that we do not know about yet.
Will I or my child be paid to complete this study?
Participants receive $50 per visit (6).
Travel can be coordinated and paid for by Tetra or reimbursed for eligible families, even if there is not a site nearby.
Who can I contact for more information about this study?
There are several sites across the U.S. Complete the contact form below to notify the site nearest you!
Site | Coordinator | Phone | |
---|---|---|---|
Rush University Medical Center (IL) | Abigail Ayemoba | abigail_ayemoba@rush.edu | 312-942-2815 |
Cincinnati Children’s Hospital Medical Center (OH) | Jessie Michael | jessica.michael@cchmc.org | 513-517-1550 |
UC Davis Health System (CA) | Abigail Higareda Borbe | amoradelhigareda@ucdavis.edu | 916-703-0281 |
Children’s Hospital Colorado (CO) | Erika Peterson | erika.peterson@childrenscolorado.org | 720-777-8590 |
Kennedy Krieger Institute (MD) | Maria Halaguena | halaguena@kennedykrieger.org | 443-923-3826 |
Icahn School of Medicine at Mount Sinai (NY) | Venus Fan | venus.fan@mssm.edu | 929-989-7016 |
University of Utah and Primary Children’s Hospital (UT) | Hina Yazdani | hina.yazdani@hsc.utah.edu | 801-581-7234 |
University of Massachusetts Medical School (MA) | Taylor Merk | taylor.merk@umassmed.edu | 774-455-4119 |
Suburban Research Associates (PA) | Augusto Sanchez | asanchez@suburbanresearch.com | 610-891-9024 x 1112 |
Greenwood Genetic Center (SC) | Nicole Johnston | njohnston@ggc.org | 864-672-6896 |
CHOC Thompson Autism Center (CA) | Mai Ngo | pngo@choc.org | 714-509-8300 x 32683 |
Emory University School of Medicine (GA) | Jean Luan McColl | jean.luan@emory.edu | 404-778-8619 |
University of Kansas Medical Center (KS) | Jasli Bonilla | jbonilla@kumc.edu | 913-945-9790 |
Amnova Clinical Research (CA) | Maggie Wang | maggie@amnovaresearch.com | 323-348-0956 |
Clinic for Special Children (PA) | Joelle Williamson | jwilliamson@clinicforspecialchildren.org | 717-687-9407 |
Interested in Participating?
Our Most Recent Opportunities
Brain & Behavior Study
Researchers at Purdue University are conducting a natural history research study to learn about brain activity in females, ages18-60 years, living with the FMR1 premutation.
NFXF Gene Therapy Community Survey
Help the NFXF - share your thoughts on gene therapy.
Study: Mechanisms and biomarkers of disease progression in Fragile X-associated tremor/ataxia syndrome (FXTAS)
The University of Kansas BRAIN Lab is conducting a research study to learn about behavioral and brain differences associated with the Fragile X premutation. Males and females ages 50-80 living with the Fragile X premutation, with or without FXTAS, may be eligible to participate. The study includes remote & in-person visits at the University of Kansas.
Exploring Potential Barriers to the Fragile X Syndrome Cascade Screening Process
Researchers at the University of Memphis and Cincinnati Children's Hospital Medical Center are conducting a research study exploring the relationship between barriers and the FXS screening process among family members.
Grief and Bereavement Experiences of Children with Intellectual Disabilities
Researchers at the University of Maryland are looking to understand how children with Fragile X syndrome (FXS) and other intellectual disabilities grieve the loss of a loved one. If you are the parent or guardian of a child with FXS or another intellectual disability who has experienced the death of someone in their life when they were 5-17 years old, researchers want to talk to you.
Language Learning in Children: Vocabulary Acquisition in a Meaningful Context
The University of Washington's Neurodevelopmental Language and Learning (NeuDLL) Lab is conducting research addressing how children learn words in stories and the skills that support learning. Participation is remote and can be completed from home. Sessions are scheduled at your convenience.